Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$15.45 ▼ -0.11
(-0.71%)
MKT CAP: $994.3M • VOL: 460.1K
52W L $7 52W H $23
ROARABLE / RQD
D- • 36/100
PIOTROSKI
2 / 9
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$13
MEDIAN
$17
MEAN
$18
HIGH
$21
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE CGEM TAPE
CGEM // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $18.69 | $17.77 | 2025-02-14 | $14.06 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $19.47 | $18.23 | 2025-02-06 | $14.52 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $17.61 | $17.00 | 2025-01-29 | $14.83 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $15.76 | — | 2025-01-17 | $15.14 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $13.60 | $14.68 | 2025-01-09 | $13.75 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $18.39 | $16.07 | 2024-12-18 | $13.44 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $14.99 | $15.60 | 2024-12-04 | $14.37 | -4.3% | 48% | C |